Addex and Indivior Advance GABAB PAM Candidates
Addex and Indivior Advance GABAB Positive Allosteric Modulators
Ad Hoc Announcement Pursuant to Art. 53 LR
Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing innovative small molecule allosteric modulators for neurological disorders, alongside Indivior PLC (NASDAQ/LSE: INDV), has announced the selection of clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration. Indivior has chosen a compound for future development aimed at treating substance use disorders and will take full responsibility for its ongoing development. The agreement stipulates that Addex could receive up to USD 330 million upon hitting specified regulatory, clinical, and commercial milestones, along with tiered royalties on net sales ranging from high single digits to low double digits. Additionally, Addex has exercised its option to pursue a compound to advance its own independent GABAB PAM program targeting chronic cough.
Collaboration Insights and Future Directions
"Indivior’s partnership with Addex has been pivotal in unearthing valuable candidates for substance use disorder treatments," stated Christian Heidbreder, Chief Scientific Officer at Indivior. "The complexities of this field are numerous, yet focusing on the GABAB receptor with positive allosteric modulators opens new pathways to develop urgently needed therapies. At Indivior, we are dedicated to enhancing addiction treatment sciences, aiming to deliver effective therapies for those impacted by substance use issues."
Tim Dyer, CEO of Addex, commented, "The selection of GABAB PAM clinical candidates is the product of over five years of diligent research at Addex in close partnership with Indivior. Our industrial-scale allosteric modulator discovery platform has enabled us to pinpoint specific candidates among thousands of options. We eagerly anticipate the forthcoming developments in the substance use disorder initiative led by Indivior, while our focus shifts to advancing our chosen clinical candidate for chronic cough into IND enabling studies."
Understanding GABAB Activation and PAM
Activation of the gamma-aminobutyric acid subtype B (GABAB) receptor, belonging to Family C class of G protein-coupled receptors (GPCR), is both clinically and commercially recognized. Baclofen, the generic GABAB receptor agonist known for treating spasticity, has demonstrated efficacy in several conditions, including alcohol use disorder, overactive bladder, chronic cough, and associated pain. However, its use has limitations due to side effects, rapid clearance from the system, and the potential for tolerance development. Innovative, potent, and selective PAMs that amplify GABA responses—rather than acting as orthosteric agonists like baclofen—are expected to deliver effective results with minimized adverse effects. Moreover, PAMs activate only when the natural ligand (GABA) binds to the receptor, potentially explaining the lowered tolerance associated with PAMs compared to conventional agonists.
About Addex Therapeutics
Addex Therapeutics is a dedicated clinical-stage biopharmaceutical entity concentrating on the discovery of novel small molecule allosteric modulators aimed at neurological conditions. The leading candidate from Addex, dipraglurant (mGlu5 negative allosteric modulator or NAM), is undergoing evaluation for potential future applications in recovering from brain injuries, such as those sustained from strokes and traumatic brain injuries. Meanwhile, Indivior has advanced a GABAB PAM drug candidate aimed at combatting substance use disorders and is expected to commence IND enabling studies shortly. Additionally, Addex is prioritizing its independent GABAB PAM program for chronic cough, forecasting the initiation of IND enabling studies in the near future. The company also holds a 20% equity stake in Neurosterix LLC, which is advancing several allosteric modulator programs targeting disorders including schizophrenia, mood disorders, and mild neurocognitive disorders. Addex shares are actively traded on the SIX Swiss Exchange and the NASDAQ Capital Market under the ticker symbol "ADXN".
Contact Information
Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
Email: PR@addextherapeutics.com
Mike Sinclair
Partner, Halsin Partners
Telephone: +44 (0)20 7318 2955
Email: msinclair@halsin.com
Frequently Asked Questions
What is the focus of Addex Therapeutics?
Addex Therapeutics focuses on developing innovative small molecule allosteric modulators for treating neurological disorders.
What has Indivior selected for its development?
Indivior has selected a GABAB positive allosteric modulator for development targeted towards substance use disorders.
What is the potential financial benefit for Addex from this collaboration?
Addex is eligible to receive up to USD 330 million based on achieving specific regulatory, clinical, and commercial milestones.
What are GABAB PAMs expected to offer compared to traditional agonists?
GABAB PAMs are expected to provide efficacy with fewer side effects and a reduced risk of tolerance, as they only activate when the natural ligand GABA is present.
Where can one find more information about Addex?
More information can be found on Addex's official website at www.addextherapeutics.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Global Aircraft MRO Market Forecast and Insights
- Tamasha Expands Its Reach with International Cricket Streaming
- Stock Market Outlook: Bullish Trends and Federal Reserve's Role
- Palantir Technologies and Microsoft: A Strategic Partnership
- Pineapple Energy Reports Q2 Performance and Future Outlook
- Geopolitical Risks Impact AI and Semiconductor Stocks
- Smart for Life Expands Acquisition Pipeline Strategy
- Understanding Capital Gains Tax on Home Sales
- Understanding the Silver Squatter Phenomenon Among Gen X
- Fintech360 and Nuvei Innovate Forex Payment Solutions